Market closed
Ocuphire Pharma/IRD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocuphire Pharma
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Ticker
IRD
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
14
Website
Ocuphire Pharma Metrics
BasicAdvanced
$31M
Market cap
-
P/E ratio
-$0.60
EPS
0.35
Beta
-
Dividend rate
Price and volume
Market cap
$31M
Beta
0.35
52-week high
$3.40
52-week low
$1.07
Average daily volume
123K
Financial strength
Current ratio
10.68
Quick ratio
10.414
Interest coverage (TTM)
-11.35%
Management effectiveness
Return on assets (TTM)
-21.35%
Return on equity (TTM)
-36.01%
Valuation
Price to revenue (TTM)
1.686
Price to book
0.75
Price to tangible book (TTM)
0.75
Price to free cash flow (TTM)
-2.419
Growth
Revenue change (TTM)
-63.67%
Earnings per share change (TTM)
-168.37%
3-year revenue growth (CAGR)
447.92%
3-year earnings per share growth (CAGR)
-56.76%
What the Analysts think about Ocuphire Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ocuphire Pharma stock.
Ocuphire Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Ocuphire Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Ocuphire Pharma News
AllArticlesVideos
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal
Benzinga·5 days ago
Ocuphire Pharma Announces Acquisition of Opus Genetics
GlobeNewsWire·6 days ago
Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ocuphire Pharma stock?
Ocuphire Pharma (IRD) has a market cap of $31M as of October 28, 2024.
What is the P/E ratio for Ocuphire Pharma stock?
The price to earnings (P/E) ratio for Ocuphire Pharma (IRD) stock is 0 as of October 28, 2024.
Does Ocuphire Pharma stock pay dividends?
No, Ocuphire Pharma (IRD) stock does not pay dividends to its shareholders as of October 28, 2024.
When is the next Ocuphire Pharma dividend payment date?
Ocuphire Pharma (IRD) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocuphire Pharma?
Ocuphire Pharma (IRD) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.